ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2023

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason.

Giammarco Mocci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.